We propose arming oHSVs with an NKG2D BiTE as a novel strategy to mediate two distinct therapeutic effects against heterogenous GBM tumors, targeting cytotoxicity towards both GSCs and bulk differentiated GBM cells. This evidence concerns the gene KLRK1 and glioblastoma.